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Abstract 
 
 
 
Alzheimer’s disease (AD) impairs long-term memory of both verbal and visual 
information. While these impairments have been studied extensively at traditional short-term 
delays of 20-35 minutes, they have not been explored at long-term delays. In the current study, 
long-term delays of 1 day and 7 days were introduced to traditional short-term memory 
measures. 60 Participants were recruited for the study including; 20 individuals with Early AD, 
20 individuals at risk for AD, and 20 age matched healthy controls. During an initial visit 
Participants were administered a self-evaluation questionnaire, the Mini Mental Status Exam, the 
Alzheimer’s disease Caregiver Questionnaire, 2 subtests from the Wide Range Assessment of 
Memory Learning, 2nd Edition (WRAML2: Story Memory and Verbal Learning subtests), the 
Wechsler Adult Intelligence Scale, 4th Edition (Information subtest), and Rey-Osterrieth 
Complex Figure Test (ROCFT). 1-day and 1-week later, Participants were administered the 
WRAML2 subtests and ROCFT as an assessment of long-term memory. 
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Early AD Participants performed significantly poorer at the 1-day interval than both the 
healthy control group and at-risk group, while performance at the 7-day interval showed less 
variation across groups. This pattern was evident across all measures administered, except the 
self-evaluation questionnaire. Results indicate adding a 1-day interval for assessment of long-
term memory using a word list task (WRAML2 Verbal Learning subtest) to a clinical AD 
screening provides increased diagnostic sensitivity to detect impairment of Early AD individuals.
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Chapter 1 
 
 
 
Introduction 
 
 Alzheimer’s disease (AD) is one of the most prominent subtypes of dementia in the 
United States (Welsh-Bohmer & Warren, 2006). Research on AD began in the early 20th century 
when Alois Alzheimer reported that his patient, Auguste D., who had shown memory 
impairments, had neurofibrillary tangles and amyloid plaques in her brain upon autopsy. Since 
then, the pathology and neuropsychology of AD has been studied and much new information has 
been revealed (Welsh-Bohmer & Warren, 2006).  
Memory and Aging 
 Memory is a basic cognitive function that tends to go unnoticed until it begins to fail. As 
individuals age, the ability to encode new memories of events or facts and working memory 
shows decline in both cross-sectional and longitudinal studies (Hedden & Gabrielli, 2004). 
Because of the cumulative effect, typically the older the individual, the more these changes are 
likely to negatively affect memory. In normal aging, short-term and remote memory are less 
negatively affected than recent memory retrieval which may be witnessed in the “forgetting” of 
the names of individuals recently met or retrieval of other novel information recently 
encountered. These and many other common memory phenomena are known because of an 
extensive research literature of memory.  
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The first systematic study of human memory was performed in Germany by Ebbinghaus 
in the 1880s (Ebbinghaus, 1885). Ebbinghaus investigated a wide range of memory 
characteristics which would eventually be known as immediate memory, distributed practice, 
chunking, meaningfulness, intentional and spontaneous recall, memory decay, incremental 
learning and resultant savings, rehearsal, and interference (Miyake & Shah, 1999). Many of these 
concepts are still considered foundational and have clinical utility. Another important 
contribution are Ebbinghaus’ “learning” and “forgetting curves” that quantitatively display the 
acquisition and decay of new information over time. Surprisingly, little clinical application has 
been based on this acquisition and decay paradigm. 
In the last 10 to 15 years, a general consensus view of memory has begun to emerge 
stressing the active, dynamic, and multi-systemic nature of memory, involving the interaction of 
such factors as long-term memory (LTM), short-term memory (STM), executive functions that 
control and regulate mental actions, and the knowledge and skills of the learner (Kintsch, 1999). 
STM is important to LTM since, in a sense, STM feeds the LTM system with new information 
by briefly storing the information before consolidation into LTM. 
LTM research since Ebbinghaus’ initial investigations has primarily focused on and been 
limited to memory development and retention over extended periods of time (Howe, 2000), 
memory decay in association with projected rate of decline (Fajnsztejn-Pollack, 1973), and 
differences in LTM acquisition skills and retention (Howe & Hunter, 1986). The methods and 
research by which LTM has been evaluated have varied widely. Research on LTM has typically 
examined its change over time without using standardized measures of assessment or measures 
with known psychometric properties such as reliability (Howe, 2000). Storage in LTM is based 
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on relatively permanent changes in brain cell structure, although there does not appear to be a 
single local storage site for stored memories (Lezak, 1995). When information is recalled after an 
hour or even a year, the information is located and retrieved from LTM (Lezak, 1995).  
One consistent finding is that long-term memory is an especially vulnerable cognitive 
system (Howe, 2000). Many neurodegenerative diseases can cause long-term memory loss, and 
currently the most prevalent and intensely researched neurodegenerative disease, Alzheimer’s 
disease, is characterized by significant LTM loss, even in its early stages.   
Alzheimer’s Disease (AD) 
 AD continues to become an increasing area of psychological research given the increased 
life expectancy growing population of individuals likely to be affected by the disease. AD is 
therefore a serious problem and early identification and treatment becomes the responsibility of 
medical and psychological professionals to diagnose accurately and develop effective treatment 
plans in the early stage of disease progression. 
AD accounts for 50%-70% of all cases of adult dementia (Neugroschl & Sano, 2009). 
The incidence of AD rises exponentially with advancing age; for example, 10 % incidence is 
reported at age 65 with an increase to 50% reported at age 85 (Neugroschl & Sano, 2009).  Men 
and women are equally at risk, however more women are affected since AD is a disease of the 
elderly and women have a longer average life span than men. These gender differences are 
congruent across all age groups and ethnic differences (Neugroschl & Sano, 2009). 
Approximately 30% of individuals with AD have a biological family member with AD 
(Neugroschl & Sano, 2009). AD is a progressive disease whose clinical course varies, with some 
people having the disease for their last 2 to 3 years of life while others may live with AD for up 
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to 20 years. AD’s progressive decline is most typically characterized by memory loss, but 
language deterioration, visios-spatial impairment, poor judgment, novel problem solving, and an 
indifferent attitude are also common symptoms (First & Tasman, 2005).  
In the early 1900s, Alois Alzheimer published a medical case report of a 55-year-old 
female patient suffering from what was described as a progressive dementia. Autopsy 
subsequently revealed an abnormal number of plaques and tangles not typical of traditional 
dementia (Albert & Moss, 2002). Alzheimer was later credited for discovering this unique form 
of dementia whose symptoms were not acknowledged in individuals younger than 65. However, 
in the 1970s, more refined diagnostic criteria were published reducing the age of suspected onset 
by at least a decade (Albert & Moss, 2002).  
Currently the Diagnostic Statistical Manual, Fourth Edition (DSM-IV-TR) labels AD as 
Dementia of the Alzheimer’s Type (American Psychiatric Association [APA], 2005). An 
individual diagnosed with Dementia of the Alzheimer’s Type must demonstrate multiple 
cognitive deficits manifested by both memory impairment and at least one additional cognitive 
disturbance including aphasia, apraxia, agnosia, or executive functioning. Further, the DSM-IV-
TR requires that the cognitive disturbances cause significant impairment in social or 
occupational functioning and represent a gradual onset and progressive cognitive decline (APA, 
2005).  
The AD deficits must cause significant impairment, be marked by gradual onset and 
progressive decline, and not be caused by another neurodegenerative disorder (APA, 2005). AD 
is classified with or without a behavioral disturbance and with early (before and up to age 65) or 
late-onset (after 65; (APA, 2005).  
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Memory and AD  
 LTM is clinically significant because of its susceptibility to gradual developmental 
decline, especially within elderly populations (Morrison, Allardyce, & McKane, 2002). 
Generally LTM is defined as an individual’s ability to store new information and recall the 
stored information after few minutes or more. The time span when STM ends and LTM begins 
has not been clearly defined and is somewhat arbitrarily set, although generally STM is seldom 
characterized as lasting beyond 30 seconds (Morrison, Allardyce, & McKane, 2002).  
LTM is of particular interest, considering the majority of measures used in assessing AD 
and other forms of cognitive decline focus primarily on short-term memory (Nygard, 2003). 
LTM struggles may exist for individuals with early-stage AD past the traditional 15-minute 
delay used in popular short-term memory measures. Of particular interest are the mechanisms 
underlying the neurocognitive processes in early onset stages of AD. Patients with AD exhibit 
cognitive impairment in the years preceding a clinical diagnosis (Forstl & Kurz, 1999). Memory 
impairments are particularly pronounced, but the relative degree to which other cognitive 
functions are impaired and the speed with which they decline during the pre-clinical years 
remain unclear (Arnaiz & Almkvist, 2003). 
Fleishman and Gabriel performed a detailed study of 11 patients over three years 
proceeding the first year of non-normal diagnosis, or potential indication of early-stage AD. The 
researchers attempted to characterize and identify the neural and psychological bases of LTM 
failure in AD. Data were collected via convergent volumetric neuro-imaging and revealed that 
performance declines rapidly in all areas of cognitive functioning but abilities sub served by the 
medial and lateral temporal lobes (i.e., memory tract locations) appeared to be substantially more 
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impaired with greater loss of episodic, implicit, and semantic memories (Fleishman & Gabrieli, 
1999). This loss of episodic, implicit, and semantic memories appears to be neurologically 
related to early-stage limbic-diencephalic pathology (Fleishman & Gabrieli, 1999). Non-
mnemonic impairment was specifically related to later-stage temporal-neocortical pathology 
(Fleishman & Gabrieli, 1999). 
 Other research studies have examined pharmacological means of delaying deterioration 
in AD using donepezil hydrochloride (Aricept™) to treat early AD symptoms of memory loss 
(Coubrough, 2008). Cholinesterase inhibitors such as Aricept remain the primary 
pharmacological treatment for AD and are used to slow symptoms of AD by acting on the 
acetylcholine activity in the brain and reducing acetylcholine levels by as much as 90% in AD, 
inhibiting the neurotransmitter acetylcholinesterase. Common cholinesterase inhibitors 
prescribed for AD currently include medications with the trade names Aricept, Nameda, Exelon, 
and Razadyne. NMDA receptor antagonists may also be prescribed to block the excitotoxicity of 
the neurotransmitter glutamate at NMDA receptors, however these are less prescribed due to 
evidence of clinical efficacy (Gourley & Eoff, 2009).  
 Despite the considerable amounts of clinical and empirical attention give to AD, making 
an accurate diagnosis is still considered controversial. Significant effort has gone into clarifying 
biological and psychological indicators for AD, however none of these indicators have been 
widely accepted due to differences in origin and a precise primary symptomology (Jelicic, 
Bonebakker, & Bonke, 1995). AD is currently described as a clinical diagnosis arrived at by 
exclusion in order to account for the progressive change in cognitive functioning (APA, 2005). 
Nevertheless, there is consensus that AD consists of neurodegeneration of the brain disrupting 
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the ability to create and retrieve memories (APA, 2005). Further, early-stage AD is defined as 
the period of time in which an individual first experiences signs and symptoms of AD that 
interfere with daily functioning. The signs and symptoms include observable cognitive decline, 
becoming forgetful of recent events or details, impaired mathematical ability, and a diminished 
ability to carry out complex tasks (Jelicic et al., 1995). 
 A review of the neuropsychological literature on long-term memory deficits in AD 
suggests that individuals demonstrate a significant deficit in explicit memory, a less severe 
deficiency in implicit memory for both verbal and visuo-spatial information, and relatively 
preserved implicit memory for visuo-motor skills (Carlesimo & Oscar-Berman, 1992). The 
majority of recent long-term memory and AD research has focused on the decline of previously 
learned information and impairment in short-term and long-term implicit memory (Jelicic et al., 
1995). The PsychInfo search engine reveals six studies that deal with AD and long-term 
memory, three of which using a similar context as the present study. These three previous studies 
highlighted results and findings relating AD and impairment in LTM (Backman, Jones, Berger, 
Laukka, & Small, 2005; Mickes, Wixted, Fennema-Notestine, & Galasko, 2007; Rogers et al., 
2006). These three studies focused primarily on early detection of early long-term memory 
defects via behavioral observations and visual-spatial assessment. 
In the first study, 1,207 preclinical AD cases were examined in order to determine the 
degree of impairment across various cognitive domains (Backman et al., 2005). Preclinical AD 
was defined in the study as the early signs of impairment in global cognitive ability. Participants 
for the study were obtained as volunteers from an aging resource center in Stockholm, Sweden. 
The results revealed larger preclinical effect size deficits in global cognitive ability, episodic 
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memory, perceptual speed, and executive functioning, and smaller effect size deficits in verbal 
ability, visual-spatial skill and attention. Individuals 75 years and younger with shorter follow-up 
intervals of three years or less revealed larger effect sizes for both global cognitive ability and 
episodic memory. Episodic memory differences were evidenced in pre-identified clinical 
individuals in terms of baseline cognitive impairment. Within episodic memory, both delayed 
testing and recall-based assessment also resulted in larger effect sizes. The authors concluded 
that deficits in multiple cognitive domains (including memory) were evident several years prior 
to AD diagnosis, and multiple brain structures and functions were affected long before the AD 
diagnosis is made (Backman et al., 2005). The deficits identified in multiple cognitive domains 
were more characteristic of LTM than STM based on episodic memory decline (Backman et al., 
2005). 
In the second study, the decline of semantic memory as a symptom in persons eventually 
diagnosed with AD was also researched (Rogers, Ivaniou, Patterson, & Hodges, 2006).  
Participants used in the study included 36 individuals who participated on a volunteer basis, with 
concerns regarding noticeable cognitive decline. The authors focused on semantic dementia as a 
point of emphasis to assess AD using category fluency and letter fluency. Semantic memory was 
defined as the conscious recollection of factual knowledge and general information about the 
world. Assessment measures used included the Booklet Category Test, the Information and 
Comprehension subtests from the WAIS-III, and a letter fluency measure designed for the study.  
Results revealed that early on individuals eventually diagnosed with AD were more impaired in 
category fluency than letter fluency. Results also revealed that individuals with AD performed 
worse on tasks associated with naming (information subtest) than with comprehension tasks 
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(comprehension subtest). Individuals eventually diagnosed with AD also revealed deficits in 
semantic and verbal comprehension suggesting a semantic decline (Rogers et al., 2006). The 
decline in semantic memory suggests impairment in LTM rather than STM in the individuals 
eventually diagnosed with AD (Rogers et al., 2006). 
The third study that examined long-term memory in those with AD was a longitudinal 
investigation that focused on impairment in neuropsychological tasks using a preclinical AD 
group. The authors defined AD as a decline in cognitive functioning served by the medial and 
lateral temporal lobes (episodic and semantic memory, respectively). Patients were obtained 
from an Alzheimer’s disease research center. The authors examined the degree of impairment 
using an evaluation of 11 individuals until an AD diagnosis was made. Individual test scores 
over time suggested decline in semantic and episodic memory more than frontal lobe functioning 
(Mickes et al., 2007). The decline in both episodic and semantic memory indicates LTM 
impairment as the 11 individuals progressed towards an eventual AD diagnosis (Mickes et al., 
2007). 
 Based on the three studies just described, a gap in the literature exists related to the 
assessment of LTM in individuals with early signs of AD. While previous research has focused 
on components of LTM including verbal, episodic, semantic, and visual memory, the studies 
have failed to examine potential decline at intervals longer than the traditional 15- to 30-minute 
delay. Based on Ebbinghaus’ research noted earlier, more pronounced declines might be 
especially obvious as the client approached a 24-hour delay.  
 Despite the fact that LTM is a cognitive process worthy of investigation, none of the 
current clinical measures evaluate memory decay beyond intervals of 15-30 minutes. Measuring 
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memory decay over a longer period (e.g., hours or days) may be crucial in assessing early 
cognitive decline in aging adults eventually diagnosed with AD. It is important to detect 
potential cognitive decline in explicit and implicit LTM; this may be more accurately done using 
intervals longer than the traditional 15-30 minutes. It may also be important to monitor the nature 
and pattern of LTM decline in early-stage AD. This study will compare traditional memory 
decay intervals with more extended intervals, specifically delays of one day and one week. 
Commonly used short-term measures will be adapted to measure LTM loss in early-stage 
Alzheimer’s patients. 
 A study in which current STM measures including the Wide Range Assessment of 
Memory and Learning, Second Edition (WRAML2) Story Memory and Verbal Learning 
subtests, along with the Rey Complex Figure Test (ROCFT) were used to measure performance 
at 24-hour (T3) and 7-day (T4) intervals with non-clinical older adults. The sample of older 
adults included 30 individuals between the ages of 55 and 75, recruited on a volunteer basis for 
participation in the study. Results revealed continuing psychometric viability for these subtests 
when used to assess retention well beyond the existing immediate (T1) and 15-minute delay (T2) 
intervals (Frise & Adams, 2009); that is, enough performance variability remained in order to 
detect varying levels of deficit. Claims for continued psychometric viability were based on the 
fact that scaled scores were found 2.0 standard deviations or more below the respective subtest 
T2 means. Scaled scores on the Story Memory subtest revealed possible scaled scores 3.0 
standard deviations or more below the subtest’s mean at T3 and T4 (Frise & Adams, 2009). 
Scaled scores on the Verbal Learning subtest revealed scoring possible scaled scores of 2.0 
standard deviations or more below the subtest’s mean at T3 and T4 (Frise & Adams, 2009). 
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Scaled scores on the ROCFT also revealed performance more than three standard deviations 
below the mean at T3 and T4 (Frise & Adams, 2009).  This study provides support for the 
potential use of current STM measures in the assessment of LTM at delays, especially in clinical 
groups for which longer-term retention is especially impaired. 
As already noted, current memory assessments use measures of immediate recall 
followed by 15 to 30 minutes later with measures of delay recall.  This paradigm may provide a 
less robust early estimate of impairment in older persons who will eventually manifest more 
convincing symptoms that currently justify the diagnosis of AD. The purpose of this proposed 
study is to assess the relative diagnostic sensitivity of LTM measures compared to currently 
utilized measures using a group of individuals with early-stage Alzheimer’s disease. 
 This study is the first that examines the diagnostic utility of using longer-term memory 
measures created from modified short-term neuropsychological memory measures to detect 
early-stage AD. Because accurate diagnosis and early treatment can lead to interventions that can 
slow the progression of the disease, early detection in AD is critical.  In this study, the sensitivity 
of several categories of measures will be evaluated in their sensitivity to distinguish between 
those suspected of being in the early stages of AD from those who are considered to be 
functioning within normal limits for age. The general domains chosen for this study include 
screening measures commonly used in clinical settings for detecting early signs and symptoms of 
AD, a self-evaluation measure, and both verbal and visual memory tests.   
AD diagnostic accuracy might be improved if longer-term memory assessment was 
performed in conjunction with current clinical screening measures. Three brief cognitive 
screenings used to identify early-stage AD were also included in this study given their 
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practicality in clinical/medical settings and reported detection of early AD symptoms. Because it 
is relatively unknown how non-AD individuals living in a retirement home would perform on the 
specific neuropsychological assessments included in this study, 20 non-AD controls were 
recruited in this study. It was important to compare the two diagnostic groups to a non-AD group 
in a similar environment.  
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Chapter 2 
 
Methods 
Participants 
Participants in this study were 60 people ranging from ages 55 to 75 residing in 
residential care facilities or nursing homes in Oregon. The sample was comprised of three 
subgroups: a non-AD subgroup (n = 20), an at-risk for AD subgroup (n = 20), and an early-stage 
AD subgroup (n = 20). Inclusion criteria for each group are listed below. Using 60 Participants 
allowed an effect size (Cohen’s d) of .80 or higher across the three groups. Using a significance 
level of p ≤ .05 (Cohen, 1998) increased the likeliness of statistical significance across groups 
given a sample size of 60. For each hypothesis in the current study, power was established at .80 
in order to increase the probability of rejecting the null hypotheses and avoid type II errors.  
Care facilities and contact information for the facilities willing to participate in the study 
are included in Appendix A. Participating care facilities were selected on the basis of existing 
relationships with the author through participation in an AD Caregiver Support Group. Of the 
two care facilities approached, both agreed to participate. Each was located in Oregon and had 
specialized units for cognitive-related disorders. However, both of the care facilities also 
provided residential care to spouses of individuals with cognitive-related disorders, as well as an 
array of chronic medical problems. All eligible Participants for this study were required to be 
residing within one of the two selected residential care facilities at the time of participation, and 
were required to not have a current diagnosis of a cognitive-related disorder. Participants were 
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representative of individuals residing at the two care facilities without a cognitive-related 
disorder diagnosis. The Participants’ reasons for residing in the two care facilities was a result of 
various medical conditions estimated as cardiovascular (15%), musculoskeletal (5%), infectious 
(5%), or respiratory disease (20%) or as spouses or family members of residents with cognitive-
related disorders such as dementia, AD, and Parkinson’s disease (55%). Eligibility was 
determined based on the criteria listed above as well as a review of each of the potential 
Participant’s medical record by facility coordinators with a master’s degree or higher at both care 
facilities. 
Participants’ records were screened based on the criteria above to assure they did not 
have a previous AD diagnosis made by a physician or psychologist within 12 months prior to 
eligibility for this study. Potential eligibility for the current study was performed using a 
thorough medical record review to assure eligible Participants did not have an existing or 
previous diagnosis of a cognitive-related disorder that staff at the care facilities may not have 
been aware of. Medical record review was performed by the respective care facility coordinating 
staff members. Eligibility for the current study was determined by care facility coordinating staff 
review of medical records and observations from residential staff members regarding residents 
whom staff members had expressed concerns about possible early cognitive decline but lacked a 
pre-existing AD diagnosis. “Expert” status was based on an education level of a master’s degree 
or higher in nursing (Country Side Coordinator) or medical administration (Edgewood Downs 
Coordinator) along with at least three years working the in a field of geriatric care, and currently 
employed as a patient “Coordinator” at the two residential care facilities that participated in the 
study. Each coordinator (one per facility) identified and classified potential Participants into one 
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of the three subgroups (non-AD, at-risk AD, and early-stage AD) based on direct observation of 
residents, discussion with residential care facility staff, signs and symptoms of AD, and their 
knowledge of individuals residing in the respective residential care facilities. 
The two residential care facility coordinators were given an example of the Participant 
informed consent form (found in Appendix B) prior to the administration of any test measures. In 
similar fashion, the two care facilities were provided with an example of the caregiver informed 
consent form (found in Appendix C). Caregiver consent forms were provided to facility staff 
responsible for daily direct care of potential Participants. Caregiver consent forms were not given 
to family members of research Participants due to Participants’ legal status to sign their own 
individual consent forms. Participants were provided with Participant Consent Forms (found in 
Appendix B) and staff members were provided with a Caregiver Consent Form (found in 
Appendix C) prior to their research participation, which was required to be completed prior to 
data collection. Participant and Caregiver Consent Forms were reviewed by this writer prior to 
the start of assessment to assure consent on behalf of the Participant and Caregiver for research 
participation.  
Measures 
Immediately following the completion of consent forms, Participants were administered a 
list of seven self-evaluation questions designed to identify each Participant’s perceived memory 
abilities. This short list of questions provided a self-evaluation of memory functioning prior to 
the administration of memory tasks. The list of self-evaluation questions can be found in 
Appendix D. Administration of the list of self-evaluation questionnaire took approximately three 
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minutes. These questions were included in order to obtain a self-evaluation of memory 
functioning. 
Immediately thereafter, the Mini Mental Status Exam (MMSE) was administered. The 
MMSE is a commonly used screening tool for psychologists and a brief quantitative measure of 
gross cognitive status, used to screen for severity of impairment at a given point in time 
(Folstein, Folstein, & McHugh, 1975); the content of the MMSE is found in Appendix E. 
Administration of the MMSE took approximately eight minutes. Scores on the MMSE can range 
from 0 to 30; a MMSE score between 20 and 25 suggests potential early cognitive decline based 
on MMSE norms for ages 55-75 (Folstein et al., 1975). Scores between 26 and 30 suggest 
normal cognitive functioning, while scores below 25 are indicative of varying degrees cognitive 
impairment based on norms for ages 55-75 (Folstein et al., 1975). Research has shown that 
clinical MMSE AD cut scores were established using 2 standard deviations based on a non-
clinical sample of individuals between the ages of 55 and 75 (Folstein et al., 1975). The MMSE 
has shown near 80% specificity in the diagnosis of AD with a clinical sensitivity between 80-
90% for AD when scores between 20 and 25 are achieved (Folstein et al., 1975). Previous 
research has not defined a mild or early AD range for MMSE scores.  
The Alzheimer’s Disease Caregiver Questionnaire (ADCQ) was also administered to the 
care facility staff identified as direct caregivers of Participants with a frequency of one ADCQ 
administered per caregiver per participant (found in Appendix F). Administration of the ADCQ 
took approximately 10 minutes. The ADCQ is a computer-based assessment measure that reports 
pre-screening success at a level of 83-91% accuracy for AD (Solomon & Murphy, 2002). These 
pre-screening success rates were determined when individuals were administered the ADCQ 
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prior to a full battery of cognitive measures resulting in positive diagnoses for AD (Solomon & 
Murphy, 2002). The ADCQ and MMSE provided useful information in the identification of 
typical AD symptoms and behaviors. Both of the selected screening measures were chosen for 
this study due to clinical relevance, ease of administration,  common utilization by physicians 
when formulating an AD diagnosis (Kaufman, Solomon, & Salisberry, 2003), and use in 
previous related research (Kaufman et al., 2003). 
Memory was assessed using portions of a common memory measures, the Wide-Range 
Assessment of Memory and Learning, Second Edition (WRAML2; Sheslow & Adams, 2003). 
The WRAML2 is designed to provide estimates of verbal and non-verbal memory functioning 
from 5 to 90 years of age. For the purpose of this research, Participants were administered two 
WRAML2 subtests, Story Memory and Verbal Learning. A description of the subtest procedure 
and the directions are included in Appendix G (Story Memory) and Appendix H (Verbal 
Learning). The WRAML2 was selected based on accessibility and attention to the specific needs 
of this current study to measure verbal memory deficits perceived in early-stage AD. Given the 
importance memory plays in AD (First & Tasman, 2005), the WRAML2 subtests provided an 
appropriate measure of verbal memory. 
The WRAML2 Story Memory subtest consists of the narration of a short story of a few 
paragraphs, followed by the Participant retelling the story. This is followed by a second story 
that is also narrated and immediately followed by a retelling. The WRAML2 Story Memory 
subtest was used since it utilizes memory demands similar to those found in everyday 
conversation or passive listening. The WRAML2 Story Memory subtest Immediate Recall task 
consisted of narration of both stories and lasted approximately 8 minutes. The scaled score from 
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the Immediate Recall task performance represented the Participant’s performance for the 
Immediate Recall phase.  
Approximately 15 minutes later, and without forewarning, the Participant is asked to 
recall both stories (without the stories being repeated). This is called the Story Memory Delay 
Recall phase. Administration of the delay recall phase took approximately 4 minutes. The scaled 
score from the Delay Recall task performance represented the Participant’s performance on the 
Delayed Recall phase. For both the Immediate and Delay Recall phases, the number of story 
items identified was totaled for a raw score, which was then converted to a scaled score (M = 10, 
SD = 3), using age-based norms found in the WRAML2 Test Manual (Sheslow & Adams, 2003).  
The WRAML2 Verbal Learning subtest was also used. With this procedure, Participants 
were asked to recall a list of 16 nouns over four learning trials. This common learning and recall 
format was useful since it required new learning and recall of seemingly unrelated information, 
such as found with a grocery list or details within a set of directions. At the end of each learning 
trial the Participant was asked to recall as many words as could be remembered. The total 
number of words remembered over the four learning trials yielded a raw score that was then 
converted to an age-related scaled score using the WRAML2 norms from the Test Manual (M = 
10, SD = 3). Test-retest correlation coefficients for the WRAML2 subtests of Story Memory and 
Verbal Learning subtests are shown in Table 1. 
Approximately 15 minutes later, and without forewarning, the Participant was again 
asked to recall the words (without the words being repeated). This was called the Delay Recall 
phase. For the Delay Recall phase, the number of the 16 words identified was totaled and 
converted to an age-related scaled score using the WRAML2 norms (M = 10, SD = 3).   
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Table 1 
Test-Retest correlation coefficients for WRAML2 Story Memory and Verbal Learning subtests, 
and ROCFT.  
 
 
Procedures 
 
Test-Retest Reliability  
(Immediate Recall) 
 
 
Test-Retest Reliability  
(Delay Recall) 
 
WRAML2 Story Memory 
 
.75 
 
.78 
WRAML2 Verbal Learning .78 .73 
ROCFT  .76 .89 
 
Note: WRAML2 = Wide Range Assessment of Memory Learning, Second Edition; ROCFT = 
Rey Osterrieth Complex Figure Test. 
 
In this investigation, two additional phases were added to both the Story Memory and 
Verbal Learning procedures in order to create a longer-term measure of verbal memory. 
Specifically, after approximately 24 hours following the administration of the Immediate and 
Recall phases, each Participant was contacted by telephone and asked again to recall the stories 
and list of words without forewarning. A telephone call was used rather than an office visit since 
this would be a practical procedure for most practitioners, plus it did not create undue hardship 
on the Participant having to schedule an additional appointment. This 24-hour recall phase will 
be referred to as the T3 phase (with T1 being the Immediate Recall phase and T2 the Delay 
Recall phase).  
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A final recall trial occurred seven days following the T1 and T2 phases. This was labeled 
the T4 phase. Again, the Participant was telephoned and asked to recall each of the stories and 
list of words without forewarning and without the stories or words being repeated. However, 
each Participant was notified of there would be two follow-up telephone calls when obtaining the 
Participant’s consent. Time required for each test component as well as total time for all aspects 
of T1 – T4 phases is found in Table 2.  
The Rey Osterrieth Complex Figure Test [ROCFT] (Meyers & Meyers, 1995) was also 
administered to Participants. The ROCFT is another widely used neuropsychological procedure; 
it is designed for the assessment of spatial processing, visual memory, and executive functioning.  
It was used in this study to assess visual memory decay over time in reference to long-term 
memory. The ROCFT consists of three test conditions: Copy, Immediate Recall, and Delayed 
Recall. The ROCFT requires Participants to draw one complex figure consisting of eleven 
interconnected and nested components, each one given one point for being drawn accurately and 
one point for being drawn in the correct location, yielding a maximum total score of 36. A third 
qualitative score, ranging from 1 (low) to 7 (high) is given for overall organization. Osterrieth 
defined the average adult score on the Copy production to be 32, and on the Recall production to 
be a 22 (Lezak, 1983). Age-related norms across ROCFT age groups indicate average ranges 
based on raw scores for a copy score between 27.0 and 36.0, an immediate recall score between 
6.5 and 20.5, and a delayed recall score between 6.5 and 20.5 (Lezak, 1983). 
The directions and procedures for the ROCFT can be found in Appendix I. and were 
followed in this study. The examiner first showed the Participant the ROCFT complex figure and 
asked the Participant to copy it. Performance on this copying was scored and constituted the  
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Table 2 
 
Content of test administration of Trial 1 through Trial 4 (T1 – T4), with estimates of the amount 
of time each procedure required.   
Time of Tasks Order of Procedures Time (minutes) 
T1 – Immediate Self-Evaluation Questionnaire 
MMSE 
ADCQ 
WRAML2 Story Memory 
WRAML2 Verbal Learning 
ROCFT Copy and Immediate Recall 
5 
8 
10 
8 
7 
10 
 
T2 – 30 minutes delay WRAML2 Story Memory Recall 
WRAML2 Verbal Learning Recall 
WAIS-IV Information 
ROCFT Recall 
 
TOTAL VISIT 1 
4 
2 
8 
7 
 
69 
 
T3 – 24 hours delay WRAML2 Story Memory Recall 
WRAML2 Verbal Learning Recall 
ROCFT Recall 
4 
2 
7 
 
T4 – 7 day delay WRAML2 Story Memory Recall 
WRAML2 Verbal Learning Recall 
RCFT Recall 
4 
2 
7 
 
 TOTAL TME  95 
 
Note: MMSE = Mini Mental Status Exam; ADCQ = Alzheimer’s Disease Caregiver 
Questionnaire; WRAML2 = Wide Range Assessment of Memory Learning, Second Edition; 
RCFT = Rey Complex Figure Test; WAIS-IV = Weschler Adult Intelligence Scale, Fourth 
Edition. 
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Copy phase score. Three minutes after copying the figure, the Participant was asked to draw the 
figure from memory. The score derived constituted the Immediate Recall score. Administration 
of both the Copy and Immediate Recall phases of the ROCFT lasted approximately 10 minutes. 
Approximately 30 minutes later, and without forewarning, the Participant was again asked to 
draw the figure from memory. The score derived was called the Delay Recall score, the Delay 
Recall phase took most Participants about 7 minutes. For Copy, Immediate and Delay Recall 
phases, points earned were determined by a scoring rubric provided by the test authors (Meyers 
& Meyers, 1995). Accordingly, raw scores were converted to T scores, using age-based norms 
(M = 50, SD = 10).  
In this investigation, two additional phases were added to the ROCFT procedure in order 
to create a longer-term measure of visual memory. Specifically, after approximately 24 hours, 
the Participant was contacted by telephone and asked to draw the figure on paper included within 
a pre-addressed and postage paid envelope addressed to the author; that envelope was provided 
during the first research visit and the Participant was told not to open it until the follow-up phone 
call. The request to again draw the figure was included in the same telephone interaction used to 
obtain the longer-term T3 Story and Verbal Learning recall tasks. The Participant was asked to 
insert the T3 drawing into the envelope and mail it within a day of the telephone call. A T4 
ROCFT recall trial also occurred seven days following the T1 and T2 phases. As part of the T4 
telephone call requests associated with the Story and Verbal Learning recall tasks already 
described, the Participant was again asked to draw the figure from memory on paper that was 
provided in a different envelope that also contained a pre-addressed and postage paid envelope 
addressed to the author. This envelope had also been given with instructions at the end of the 
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T1/T2 session. The Participant was asked to insert the T4 drawing into the envelope and mail it 
within a day of the telephone call. Each Participant was notified of the T3 and T4 telephone calls 
during consent administration, but was not told about their content. Test-Retest coefficients for 
the ROCFT are shown in Table 1. Test-retest reliability coefficients for the ROCFT Immediate 
and Delay Recall tasks are also found in Table 3.  
 
Table 3 
Test-Retest correlation coefficient for the WAIS-IV Information subtest   
Procedure Test-Retest Coefficient Scaled Score Point 
Difference Between 
Testings 
 
WAIS-IV Information  .93 .05 
 
Note: WAIS-IV = Wechsler Adult Intelligence Scale, Fourth Edition. 
 
The WAIS-IV Information subtest was also administered to each Participant as a 
commonly-used measure of long-term verbal memory. A series of orally presented questions that 
tapped the general knowledge of common events, objects, places, and people was administered 
to each Participant. This procedure was administered in the standardized manner, with the 
directions found in Appendix J. Administration of the WAIS-IV Information subtest lasted 
approximately 8 minutes. The test-retest reliability coefficient for the WAIS-IV Information 
subtest can be found in Table 3.  
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Procedure 
The researcher was blind to the group assignment made by the “expert” site coordinators. 
Blindness was maintained by having the facility coordinators select individuals to participate in 
the study, without this information being relayed to the researcher. Site coordinators kept a list of 
individuals selected and their classified group on a separate spreadsheet document that was not 
given to the researcher until data collection was complete. Participants were classified and 
selected for the study until 60 Participants had been administered the research measures for a 
total of 20 non-AD Participants, 20 at-risk Participants, and 20 early-stage AD Participants. 
Facility coordinators monitored the potential Participants being selected and kept track of how 
many individuals had been selected for each group.  
Neither Participants nor Care Facilities received financial compensation for their 
participation in this study. The primary researcher gained approval from the George Fox 
University Internal Review Board prior to beginning the research, and proceeded with an 
informed consent process. Care facility caregivers were asked to participate in the informed 
consent process and Caregiver consent forms for their participation in the current study.  
Following the informed consent process, Participants were asked to complete the list of 
seven self-evaluation questions related to memory found in Appendix C. Following the 
administration of the self-evaluation questionnaire, Participant’s were administered the Self-
Evaluation, MMSE, ADCQ, WRAML2 subtests (Story Memory and Verbal Learning), ROCFT, 
and WAIS-IV Information subtest in a randomized order. The measures administered were 
divided into 3 separate randomized forms (A, B, & C) which organized the measures mentioned 
above to allow for optimal Participant performance across measures. Randomized orders 
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consisted of Form A (Self-Evaluation, MMSE, WRAML2 subtests, ROCFT, and WAIS-IV 
Information), Form B (Self-Evaluation, MMSE, WRAML2 subtests WAIS-IV Information, and 
ROCFT), and Form C (Self-Evaluation, MMSE, ROCFT, WRAML2 subtests, and WAIS-IV 
Information).  
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Chapter 3 
 
Results 
 
Demographic information of Participants including mean age, standard deviation of age, 
and gender can be found in Table 4. A one-way ANOVA using age as the dependent variable 
yielded results that showed no significant differences across the three groups (F(2,57) = .96, p > 
.40).  Differences in gender proportions across groups were found to be non-significant (χ²(1) = 
.27, p > .60).  
 
Table 4 
Age, Size and Gender Distribution for Each Sample 
 
Group 
 
Mean Age and (SD) 
 
N 
 
Gender 
 
Non-AD 
 
69.7 
  (0.71) 
 
20 
 
11 F 
 9 M 
 
At-Risk 70.6 
  (4.95) 
20  7 F 
13 M 
 
Early-Stage AD 71.4 
   (4.24) 
20 14 F 
 6 M 
 
 
Note: AD = Alzheimer’s disease; F = female; M = male. 
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To organize the results of the analyses, each hypothesis will be re-stated in terms of the 
dependent variables analyzed in order to address the respective hypothesis related to the 3 groups 
consisting of a non-AD subgroup (n = 20), an at-risk for AD subgroup (n = 20), and an early-
stage AD subgroup (n = 20). To assess performance on the Self-Evaluation Questionnaire, 
MMSE, and ADCQ across the three groups of Non-AD, At-Risk, and Early AD group mean 
scores on each measure were used. Mean score performance was based on raw number of Self-
Evaluation items endorsed, MMSE raw scores (up to 30 points possible), and ADCQ hits (items 
endorsed by caregivers). Mean score results for each group across the three measures can be 
found in Figure 1. 
 
 
 
Figure 1. Mean performance by group on the Self-Evaluation Questionnaire, MMSE, and ADCQ 
(hits), X axis = measures and Y axis = raw scores. AD = Alzheimer’s Disease, MMSE = Mini 
Mental State Exam, ADCQ = Alzheimer’s Disease Caregiver Questionnaire. 
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To determine whether the three subgroups performed differently on the Self-Evaluation 
Questionnaire, a one-way ANOVA was conducted to compare the total raw score means for each 
subgroup. Mean total raw scores and standard deviations (found in parentheses) for each group 
were: the Non-AD group 10.9 (1.4), for the At-Risk group 10.8 (3.3), and for the Early AD 
group 10.3 (2.7). A one-way ANOVA revealed no differences between groups (F(2, 57) = .53, p 
< .05), indicating that self-evaluation of memory across the three groups did not differ. 
To determine whether there were differences between MMSE scores across the three 
groups, a one-way ANOVA was conducted using MMSE raw scores. Mean scores and standard 
deviations (in parentheses) of MMSE raw scores for the three groups were: Non-AD group 27.7 
(1.3), At-Risk group 25.2 (2.2), and Early AD group 21.2 (1.5). MMSE scores were found 
significantly different across the three groups F(2, 57) = 72.7, p < .05, eta squared = .936). Post-
hoc comparisons indicate the Non-AD and At-Risk group means did not differ, however the 
Early AD group mean differed from both the Non-AD and At-Risk groups.  
To determine whether if there was a difference between the three subgroups on ADCQ 
scores, a one-way ANOVA was conducted using total ADCQ hits (items endorsed). Mean scores 
and standard deviations (in parentheses) of ADCQ total scores for the three groups were:  Non-
AD group 0.3 (0.6), At-Risk group 5.3 (1.7), and Early AD group 11.4 (1.2). ADCQ scores for 
the three groups were found significantly different (F(2, 57) = 415.9, p < .05, eta squared =.864). 
Post-hoc comparisons indicate meaningful ADCQ differences in the Non-AD, At-Risk, and 
Early AD groups.  
Traditionally, clinicians and practitioners use MMSE raw scores and ADCQ hits to make 
decisions regarding potential symptoms of AD and the need for further diagnostic clarification. 
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To assess the consistency between AD screening measures, correlations were calculated using 
raw scores achieved on the MMSE and ADCQ hits. Inverse correlations of moderate magnitude 
were expected, due to the expectation that lower MMSE raw scores would be associated with 
more ADCQ hits and vice versa. Table 5 shows the correlations between the MMSE and ADCQ 
for the Non-AD, At-Risk, and Early AD groups. MMSE and ADCQ correlations for the Early 
AD group showed a moderate inverse correlation of r = -.31. Correlations for the MMSE and 
ADCQ among the Non- AD (r = -.08) and At-Risk (r = -.07) groups were non-significant. These 
findings show that when administered for AD screening purposes, the results generated by the 
MMSE and ADCQ in the Early AD group show inverse correlations, and are therefore 
diagnostic when used appropriately. 
 
Table 5 
Pearson and Spearman Correlations between the MMSE Raw Scores and ADCQ Hits for Non- 
AD, At-Risk, and Early AD Subgroups. 
 ADCQ  
Non-AD MMSE 
     Pearson r 
     Spearman r 
 
 
-0.08 
-.13 
At-Risk MMSE 
     Pearson r 
     Spearman r 
 
 
-0.07 
-.04 
Early AD MMSE 
     Pearson r 
     Spearman r 
 
-0.31 
-.37 
 
Note:  AD = Alzheimer’s Disease; ADCQ = Alzheimer’s Disease Caregiver Questionnaire; 
MMSE = Mini Mental Status Exam.  
Using STM Measures to Assess LTM in Early AD     30 
 
 
To assess the relationship between memory variables, as well as stability for each 
memory measure over time, correlations were calculated among scaled scores obtained at each of 
the four trials for each memory measure. Correlations of moderate magnitude were expected. All 
correlations across T1-T4 within given tasks were significant and of moderate magnitude. 
Correlations based on scaled scores for all three groups on each memory measure (WRAML2: 
Story Memory, WRAML2: Verbal Learning, and ROCFT) across the four trials can be found in 
Table 6. Correlations based on scaled scores for the Non-AD group on each memory measure 
(WRAML2: Story Memory, WRAML2: Verbal Learning, and ROCFT) across the four trials can 
be found in Table 7. Correlations based on scaled scores for the At-Risk group on each memory 
measure (WRAML2: Story Memory, WRAML2: Verbal Learning, and ROCFT) across the 4 
trials can be found in Table 8. Correlations based on scaled scores for the Early AD group on 
each memory measure (WRAML2: Story Memory, WRAML2: Verbal Learning, and ROCFT) 
across the 4 trials can be found in Table 9. These findings demonstrate that performance on a 
memory tasks (WRAML 2 subtests and ROCFT) are relatively stable over time across the three 
subgroups in this study despite anticipated declines in performance on the basis of forgetting 
over time. 
